Zai Lab and Novocure Announce EF-31 Phase II Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Zai Lab announced that the EF-31 Phase II pilot study, testing the safety and efficacy of Tumor Treating Fields together with standard-of-care as a first-line treatment in patients with gastric adenocarcinoma, met its primary endpoint of objective response rate with supportive signals across secondary endpoints.